All In Biotech

Drug Trial Radar · NCT06794957

A Study of AL8326 in Non-Small Cell Lung Cancer

A Single-Arm, Open, Phase Ib Study Evaluating the Safety, Preliminary Efficacy of AL8326 in the Treatment of Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

158

Planned (sponsor's estimate)

Start

May 19, 2022

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Advenchen Laboratories, LLCIndustry
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, single arm, open, phase IB clinical trial, designed to evaluate the preliminary efficacy and safety of AL8326 in patients with non-small cell lung cancer (NSCLC) who relapsed or progressed after multi line treatment and failed standard treatment.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • AL8326 tabletsDrug

    10mg/tablet;Oral administration, once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective remission rate (ORR)Time frame: Every 2 cycles,up to 24 months (each cycle is 28 days)

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medicaal University

    Bengbu, Anhui, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Xuancheng People´s Hospital

    Xuancheng, Anhui, China

  • Anyang Cancer Hospital

    Anyang, Henan, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • Nanjing Chest Hospital

    Nanjing, Jiangsu, China

  • Sir Run Run Shaw Hospital (SRRSH),affiliated with Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The First Hospital Of Jiaxing

    Jiaxing, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.